The endocrine system — the network of glands and organs that produce, release and regulate hormones throughout the body — is one of the most profoundly affected but least discussed systems in the context of nicotine exposure. Nicotine interacts with the endocrine system through multiple direct and indirect pathways, affecting the adrenal glands, thyroid, pancreas, hypothalamic-pituitary axis and sex hormone balance. For the growing number of adults across Ireland who vape daily — whether they buy from a high street retailer or an online vape ireland specialist — understanding nicotine’s hormonal footprint provides important context for a range of health concerns that may not, at first glance, seem connected to their vaping habit.
The Adrenal Glands and the Stress Hormone Response
The most immediate and well-characterised endocrine effect of nicotine is its activation of the adrenal glands. Nicotine stimulates nicotinic acetylcholine receptors on chromaffin cells of the adrenal medulla — the inner portion of the adrenal gland — triggering the rapid release of adrenaline (epinephrine) and noradrenaline (norepinephrine). This catecholamine surge is responsible for the familiar acute effects of nicotine: elevated heart rate, raised blood pressure, increased alertness and suppressed appetite.
Simultaneously, nicotine activates the hypothalamic-pituitary-adrenal (HPA) axis — the hormonal cascade that governs the body’s stress response. Nicotine stimulates the hypothalamus to release corticotropin-releasing hormone (CRH), which signals the pituitary to release adrenocorticotropic hormone (ACTH), which in turn stimulates the adrenal cortex to produce cortisol — the primary glucocorticoid stress hormone. Each vaping session produces a measurable cortisol spike through this pathway, with blood cortisol levels rising within minutes of nicotine absorption and remaining elevated for up to 30–40 minutes.
In the short term, this cortisol response is physiologically normal — it is the same cascade activated by exercise, psychological stress, or any sympathetic nervous system activation. The problem with chronic nicotine use is the cumulative effect of repeated HPA axis activation throughout the day. Chronically elevated cortisol baseline contributes to insulin resistance (explaining part of nicotine’s metabolic effects discussed in the diabetes companion article), impairs immune function, disrupts sleep architecture, promotes central adiposity (abdominal fat accumulation), and — over years — contributes to adrenal fatigue and HPA axis dysregulation.
Cortisol and Chronic Stress: The Overlap That Matters
Many vapers report that they vape primarily to manage stress, and there is a bitter irony in the endocrine picture here. The subjective sense of stress relief from vaping is real — it reflects both the relief of nicotine withdrawal-induced cortisol elevation (stopping the withdrawal spike) and the brief anxiolytic effect of dopaminergic reward system activation. But each vaping session that relieves subjective stress simultaneously activates the HPA axis and raises cortisol — the very hormone that, in chronically elevated states, produces many of the symptoms of chronic stress: fatigue, impaired concentration, low mood, disrupted sleep, and increased anxiety between nicotine doses.
This creates a self-sustaining cycle: nicotine use raises cortisol, elevated baseline cortisol increases anxiety and stress sensitivity, heightened stress and anxiety motivate further nicotine use for relief. The cycle is not unique to vaping — it operates identically in cigarette smokers — but it is worth making explicit for vapers who believe their use is purely stress-management. The endocrine system is, in a direct sense, the mechanism through which nicotine maintains its grip.
The Thyroid Gland: An Underappreciated Target
The relationship between nicotine and thyroid function is less intuitive than the adrenal connection but equally well-supported in the endocrine literature. Smoking is associated with measurably altered thyroid hormone levels — typically mildly elevated total T4 and reduced TSH (thyroid-stimulating hormone) — and with an increased risk of Graves’ disease (autoimmune hyperthyroidism) and worsened outcomes in thyroid eye disease (Graves’ orbitopathy). These associations are strongest for smoking but their nicotine-specificity is partially established.
Nicotine activates nAChRs on thyroid follicular cells and influences thyroid hormone biosynthesis through mechanisms that include altered iodide transport and thyroglobulin processing. Thiocyanate — a metabolite of hydrogen cyanide in cigarette smoke — is also a competitive inhibitor of thyroid iodide uptake, but this mechanism is specific to combustion and does not apply to vaping. For people with autoimmune thyroid conditions (Hashimoto’s thyroiditis, Graves’ disease), nicotine’s direct thyroid cell activation and its systemic immunomodulatory effects (discussed in the immune system article) are both relevant to disease activity and treatment response.
Clinical alert for thyroid patients: If you have Graves’ disease, particularly with eye involvement (Graves’ orbitopathy), nicotine use — including vaping — is associated with significantly worse orbital disease outcomes and poorer response to radioiodine treatment. Endocrinologists treating Graves’ orbitopathy consistently recommend complete nicotine cessation as a high-priority clinical intervention, regardless of delivery method.
Sex Hormones: Testosterone, Oestrogen and Reproductive Endocrinology
Nicotine’s effects on sex hormones represent one of the most clinically significant endocrine chapters in the vaping and health literature, with implications that extend well beyond reproductive health to include cardiovascular risk, bone density, mood regulation and cognitive function.
In men, chronic nicotine exposure suppresses the hypothalamic-pituitary-gonadal (HPG) axis through adrenergic mechanisms that reduce LH (luteinising hormone) pulsatility — the signal that drives Leydig cell testosterone production. Studies in male smokers consistently document lower total and free testosterone compared to age-matched non-smokers, with the difference attributable partly to nicotine (as demonstrated in nicotine patch studies showing similar suppression) and partly to the direct testicular toxicity of combustion compounds not present in vaping aerosol. For male vapers, the nicotine-specific testosterone suppression pathway remains active, though at a potentially smaller magnitude than in smokers.
In women, nicotine accelerates oestrogen metabolism through induction of CYP1B1 and other enzymes that convert oestrogens to less active catechol oestrogen metabolites. This oestrogenic deficiency state from accelerated oestrogen clearance contributes to the earlier menopause onset observed in female smokers, the reduced bone density (discussed in the bone health companion article), and the altered cardiovascular risk profile seen in premenopausal smoking women. Whether vaping produces equivalent oestrogen metabolism acceleration is not established — the CYP induction from combustion PAHs is not replicated in vaping aerosol — but nicotine’s direct HPG axis effects are shared.
Insulin: The Pancreatic Endocrine Connection
The pancreatic islets of Langerhans — which produce insulin, glucagon and other hormones that regulate blood glucose — are direct targets of nicotine through nAChRs expressed on both alpha (glucagon-producing) and beta (insulin-producing) cells. Nicotine acutely suppresses insulin secretion through alpha-2 adrenergic receptor activation on beta cells (the sympathoadrenal mechanism discussed in the diabetes companion article) while simultaneously stimulating glucagon release, producing a hyperglycaemic response to each vaping session. Chronic nicotine exposure is associated with progressive beta cell dysfunction in both animal models and epidemiological studies of smokers.
The endocrine framing adds important context to the metabolic effects discussed in the diabetes article: nicotine’s effects on blood glucose and insulin sensitivity are not isolated metabolic events but part of a broader endocrine disruption pattern that encompasses adrenal cortisol secretion (which independently elevates blood glucose), sex hormone changes (which alter insulin sensitivity differently in men and women), and direct pancreatic beta cell dysfunction. The cumulative endocrine effect of chronic nicotine use on metabolic health is substantially greater than any single pathway in isolation.
Appetite, Weight and Metabolic Hormones
Nicotine’s appetite-suppressing and weight-reducing effects are well-documented and represent one of the reasons people are reluctant to reduce nicotine use — many former smokers and some vapers report weight gain when they reduce or stop. The endocrine mechanisms are multiple: nicotine reduces neuropeptide Y (NPY) signalling in the hypothalamus — NPY is a potent hunger stimulant — and activates melanocortin-4 receptors (MC4R), which suppress appetite and increase energy expenditure. Nicotine also alters leptin and ghrelin levels, the key peripheral hunger-regulating hormones, in ways that reduce appetite signalling.
These appetite effects are real and physiologically significant — but they come at the cost of the broader endocrine disruption described throughout this article. The weight management properties of nicotine have historically been one of the most exploited aspects of tobacco marketing, and the same dynamic is visible in some vaping contexts. Understanding that the appetite suppression comes packaged with adrenal stress, thyroid disruption, sex hormone alteration, and metabolic dysregulation provides a more complete basis for decisions about nicotine use as a weight management tool.
Practical Guidance for Vapers Concerned About Hormonal Health
- If you have a known thyroid condition — particularly Graves’ disease, Graves’ orbitopathy, or Hashimoto’s thyroiditis — discuss vaping use explicitly with your endocrinologist. The nicotine-thyroid interaction is clinically relevant to disease management and treatment response.
- If you are experiencing symptoms consistent with elevated cortisol — persistent fatigue, difficulty sleeping, central weight gain, impaired concentration, increased anxiety between vaping sessions — these are consistent with chronic HPA axis activation from nicotine and should be discussed with a GP in the context of your vaping use.
- If you are being investigated for testosterone deficiency (in men) or hormonal irregularities (in women), ensure that your vaping status is clearly documented in your medical history. Nicotine use is a modifiable contributor to sex hormone abnormalities that should be considered alongside other causes.
- Do not use vaping as a weight management tool. The appetite-suppressing effects are real but the endocrine costs — adrenal dysregulation, oestrogen metabolism acceleration, insulin suppression, testosterone reduction — represent a poor exchange for any weight benefit achievable through sustainable lifestyle approaches.
- Progress toward nicotine reduction. Every component of the endocrine disruption described in this article is dose-dependent and partially or fully reversible with nicotine reduction or cessation. The endocrine system’s recovery from nicotine exposure — cortisol normalisation, thyroid function stabilisation, sex hormone restoration — represents some of the most clinically significant long-term benefits of quitting, and these benefits occur over a timeline of weeks to months rather than years.
